Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • Atomo Locks in US$410K Pascal Order as FebriDx Demand Accelerates in the US
    Atomo Locks in US$410K Pascal Order as FebriDx Demand Accelerates in the US
    • News

  • June 2025 quarter CPI no roadblock to August RBA rate cut
    June 2025 quarter CPI no roadblock to August RBA rate cut
    • News

  • Vection Secures $7.3M Defence Extension as AI Demand Strengthens
    Vection Secures $7.3M Defence Extension as AI Demand Strengthens
    • News

  • Calix Secures $44.9m ARENA Grant to Build Green Iron Plant with ZESTY Technology
    Calix Secures $44.9m ARENA Grant to Build Green Iron Plant with ZESTY Technology
    • News

  • Harris Technology boosts retail margins in FY25 through growth of refurbished tech
    Harris Technology boosts retail margins in FY25 through growth of refurbished tech
    • News

  • Lumos Diagnostics Secures US$317M Deal to Distribute FebriDx® in U.S.
    Lumos Diagnostics Secures US$317M Deal to Distribute FebriDx® in U.S.
    • News

  • dorsaVi Powers Ahead with High-Speed RRAM for Smarter Wearables and Edge AI
    dorsaVi Powers Ahead with High-Speed RRAM for Smarter Wearables and Edge AI
    • News

  • Nanoveu Secures $2 Million to Fast-Track Commercial Launch of ECS-DoT Chip and AIoT Platform
    Nanoveu Secures $2 Million to Fast-Track Commercial Launch of ECS-DoT Chip and AIoT Platform
    • News

  • Archer Unlocks Cryogenic Sensor Breakthrough for Quantum Computing
    Archer Unlocks Cryogenic Sensor Breakthrough for Quantum Computing
    • News

  • EGL Secures $1.9M PFAS Plant Contract as Demand for Clean-Up Technologies Surges
    EGL Secures $1.9M PFAS Plant Contract as Demand for Clean-Up Technologies Surges
    • News

Emyria recruits first patient for its meth-assisted therapy to treat PTSD

  • In News
  • July 10, 2023
  • Alinda Gupta
Emyria recruits first patient for its meth-assisted therapy to treat PTSD

As news of billionaire (and controversial) business magnate Elon Musk taking “microdoses of ketamine (a dissociative drug)” to manage depression started doing the rounds, a bunch of divisive arguments popped up—is that just an excuse to justify the use of drugs or is there some hidden potential there?

Biotech company Emyria (ASX: EMD) makes a case for the latter.

The Company has reached a key stage in its mission to expand therapy options for challenging mental health conditions. In that spirit, it has successfully recruited the first patient for its Phase 2B MDMA-assisted therapy trial, targeting Post-Traumatic Stress Disorder (PTSD). This development signifies progress in Emyria’s efforts to develop MDMA-assisted and psilocybin-assisted therapies for individuals facing significant mental health challenges. The trial aims to contribute to advancements in the field of mental health treatment.

Psychedelic-assisted therapy has emerged as a promising treatment approach for conditions like PTSD and treatment-resistant depression. The recent rescheduling of MDMA and psilocybin as controlled medicines by the Therapeutic Goods Administration (TGA)—that is, medicines that can be prescribed but have to be strictly regulated—from July 1, 2023, has opened up exciting opportunities to expand the clinical application of these new therapies.

Emyria is conducting the EMDMA-001 trial, a meticulously designed study to assess the safety, efficacy, and cost-effectiveness of MDMA-assisted therapy for PTSD. This trial aims to generate important data that can support Emyria’s leadership in delivering comprehensive psychedelic-assisted therapy within a multidisciplinary clinical service. Patient recruitment will be carefully staggered to ensure meticulous supportive care and monitoring.

Plus, the Company’s recent acquisition of The Pax Centre (a psychological trauma care service) strengthens its presence in the mental health sector. This move expands Emyria’s capacity to offer high-quality mental healthcare facilities and augment its team of 20 mental health professionals, including experts in psychiatry, mental health nursing, clinical psychology, counseling, social work, occupational therapy, and chiropractic care.

Additionally, Emyria has obtained an importation licence from the Office of Drug Control (ODC) to acquire MDMA for use in the EMDMA-001 trial. This accomplishment underscores Emyria’s commitment to regulatory compliance and its ability to navigate complex regulatory environments. By adhering to stringent Australian regulations governing the import and export of controlled substances, Emyria demonstrates its dedication to delivering innovative mental health treatments within the bounds of the law.

Emyria’s prior initiatives, including Emerald Clinics, have contributed to the Company’s expertise in the field. Through Emerald Clinics, Emyria has successfully treated patients with pharmaceutical-grade cannabinoids and harnessed its advanced data platform, Palantir Foundry, to gather comprehensive clinical data. This platform, which leverages data capture, analysis, and machine learning capabilities, has informed personalised care plans and facilitated the launch and commercialisation of various drug development programs.

Treading through risky waters, using psychedelics to treat PTSD, the Company is hoping to develop breakthrough therapies. As the EMDMA-001 trial progresses, Emyria seeks to establish a commercial delivery model that ensures specialised and well-trained clinical services make psychedelic-assisted therapy available to those in need, perhaps even putting the arguments about  Musk’s ketamine use to rest?

 

  • About
  • Latest Posts
Alinda Gupta
Alinda is a Business Reporter for The Sentiment
Latest posts by Alinda Gupta (see all)
  • Ovanti’s iSentric signs contracts worth $14.4m with Malaysian commercial bank - June 27, 2024
  • Baby Bunting fights back from retail downturn with 5-year strategy, includes Gen-Z focus and self-funded growth - June 27, 2024
  • CLEO meets with US FDA to develop strategy for ovarian cancer test launch - June 26, 2024
  •  
  •  
  •  
  •  
  • emyria
  • Palantir
  • psilocybin
  • ptsd
  • tga
  • The Pax Centre
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Alinda Gupta
Alinda is a Business Reporter for The Sentiment
Latest posts by Alinda Gupta (see all)
  • Ovanti’s iSentric signs contracts worth $14.4m with Malaysian commercial bank - June 27, 2024
  • Baby Bunting fights back from retail downturn with 5-year strategy, includes Gen-Z focus and self-funded growth - June 27, 2024
  • CLEO meets with US FDA to develop strategy for ovarian cancer test launch - June 26, 2024

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Alinda Gupta
Alinda is a Business Reporter for The Sentiment
Latest posts by Alinda Gupta (see all)
  • Ovanti’s iSentric signs contracts worth $14.4m with Malaysian commercial bank - June 27, 2024
  • Baby Bunting fights back from retail downturn with 5-year strategy, includes Gen-Z focus and self-funded growth - June 27, 2024
  • CLEO meets with US FDA to develop strategy for ovarian cancer test launch - June 26, 2024
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.